BioNTech SE (NASDAQ:BNTX) Shares Purchased by Investmentaktiengesellschaft Fuer Langfristige Investoren TGV

Investmentaktiengesellschaft Fuer Langfristige Investoren TGV increased its stake in BioNTech SE (NASDAQ:BNTX - Free Report) by 41.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 20,500 shares of the company's stock after purchasing an additional 6,000 shares during the period. BioNTech makes up 0.1% of Investmentaktiengesellschaft Fuer Langfristige Investoren TGV's holdings, making the stock its 17th biggest holding. Investmentaktiengesellschaft Fuer Langfristige Investoren TGV's holdings in BioNTech were worth $1,647,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Harding Loevner LP bought a new position in BioNTech in the 4th quarter valued at approximately $410,984,000. Primecap Management Co. CA lifted its stake in shares of BioNTech by 2.8% in the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company's stock valued at $502,735,000 after acquiring an additional 131,490 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of BioNTech by 610.5% during the 1st quarter. SG Americas Securities LLC now owns 70,143 shares of the company's stock valued at $6,471,000 after acquiring an additional 60,270 shares in the last quarter. Beacon Pointe Advisors LLC bought a new stake in BioNTech during the 4th quarter worth $5,563,000. Finally, Scotia Capital Inc. acquired a new position in BioNTech in the 4th quarter worth about $5,277,000. Institutional investors own 15.52% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on BNTX shares. BMO Capital Markets reduced their price target on BioNTech from $123.00 to $122.00 and set an "outperform" rating on the stock in a report on Tuesday, May 7th. HSBC upgraded BioNTech from a "hold" rating to a "buy" rating in a research report on Friday, August 2nd. Deutsche Bank Aktiengesellschaft raised shares of BioNTech from a "hold" rating to a "buy" rating and set a $95.00 target price for the company in a research report on Wednesday, August 7th. TD Cowen cut their price target on shares of BioNTech from $98.00 to $85.00 and set a "hold" rating on the stock in a research report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. dropped their price objective on BioNTech from $94.00 to $91.00 and set an "underweight" rating on the stock in a research note on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, BioNTech has an average rating of "Moderate Buy" and an average price target of $109.09.

BioNTech Trading Up 0.7 %

Shares of BioNTech stock traded up $0.62 during midday trading on Friday, reaching $88.22. 595,112 shares of the company's stock traded hands, compared to its average volume of 728,051. The stock has a 50 day moving average of $84.02 and a 200-day moving average of $89.33. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $125.83. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. The company has a market cap of $20.98 billion, a PE ratio of 176.44 and a beta of 0.23.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The company had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. During the same period in the previous year, the company earned ($0.86) earnings per share. BioNTech's quarterly revenue was down 23.3% on a year-over-year basis. As a group, equities analysts expect that BioNTech SE will post -2.8 EPS for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.